Oct 11th 2012 - Edison Investment Research today published a report on Tissue Regenix (TRX.L, LSE:TRX, LON:TRX) entitled "A Commercial Company". In summary, the report says:
Tissue Regenix is achieving excellent clinical results with its decellularised medical devices – natural human or porcine tissues with all cells and DNA removed. In vascular dCELL patches, stem cells rapidly colonise grafts. However, showing clear superiority takes time. Human heart valve grafts show good performance in Brazilian trials. In a human dermal dCELL graft pilot study, 45% of leg ulcers healed within six weeks. The business is well funded with £26m cash and is commercially run with vascular patch EU sales expected to start in FY14.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »